Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) When Administered to Patients With Advanced Solid Tumors
Conditions
Interventions
Lipotecan
Locations
4
United States
Medical College of Georgia
Augusta, Georgia, United States
Bidmc, Dfci, Mgh
Boston, Massachusetts, United States
Montefiore Medical Center
The Bronx, New York, United States
National Taiwan University Hospital
Taipei, Taiwan
Start Date
September 1, 2008
Primary Completion Date
August 1, 2011
Completion Date
December 1, 2011
Last Updated
November 18, 2019
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Taiwan Liposome Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions